(firstQuint)Efficacy and Safety of T1225 1.

5% Versus Tobramycin 0.

3 % in the Treatment of Purulent Bacterial Conjunctivitis.

 The aim of the present study was to compare the efficacy and safety of T1225 1.

5% eye drops administered BID for 3 days in comparison to reference antibiotic eye drops, tobramycin, for the treatment of purulent bacterial conjunctivitis.

 The study was conducted as a Phase III, multicentre, international, investigator-masked, randomised, parallel-group, non-inferiority study in newborns, children, and adults.

.

 Efficacy and Safety of T1225 1.

5% Versus Tobramycin 0.

3 % in the Treatment of Purulent Bacterial Conjunctivitis@highlight

To demonstrate the efficacy of T1225 1.

5% eye drops, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis, and to assess the safety